Therapeutic | Brodalumab |
Target | IL17RA |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS |
Light Chain | EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Abgenix XenoMouse |
INN Year Proposed | 2011 |
INN Year Recommended | 2012 |
Companies Involved | Amgen, AstraZeneca, Bausch Health Companies, Kyowa Hakko Kirin, LEO Pharma |
Conditions Approved | Erythrodermic psoriasis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis, Psoriasis |
Conditions Active | Spondylarthritis, Systemic scleroderma |
Conditions Discontinued | Asthma, Crohn's disease, Rheumatoid arthritis |
Notes |